Merck and Kelun‑Biotech’s Sac‑TMT ADC Cuts Death Risk in Phase III Endometrial Cancer Trial

Why It Matters

Endometrial cancer is the only major solid tumor with rising incidence and mortality in high‑income countries, and patients who progress after platinum chemotherapy and PD‑1/L1 blockade have few effective therapies. Demonstrating a survival advantage with an ADC offers a new mechanism of action that could shift treatment algorithms and provide a lifeline for a growing patient population. The approval would also diversify Merck’s oncology portfolio ahead of Keytruda’s patent cliff, reducing reliance on a single blockbuster and signaling the company’s ability to compete in the rapidly expanding ADC market, which is projected to exceed $30 billion globally by 2030.

Key Takeaways

• Merck and Kelun‑Biotech’s sac‑TMT met primary OS and PFS endpoints in a 776‑patient Phase III trial (TroFuse‑005).
• The trial showed statistically significant and clinically meaningful survival benefits versus physician’s choice chemotherapy.
• Safety remained consistent with earlier studies; no new safety signals were observed.
• Merck secured a Commissioner’s National Priority Voucher to accelerate potential FDA review.
• The result marks the first global Phase III win for Merck’s TroFouse ADC program, positioning it against Gilead’s Trodelvy and AstraZeneca’s Datroway.

Pulse Analysis

The sac‑TMT data arrive at a pivotal moment for Merck’s oncology strategy. With Keytruda’s revenue set to erode as patents expire, the company needs a credible successor in the immuno‑oncology space. An ADC that can deliver a survival benefit in a hard‑to‑treat indication not only diversifies Merck’s pipeline but also gives it a foothold in the lucrative ADC arena, where competition is intensifying. The priority review voucher further shortens the regulatory timeline, potentially allowing Merck to bring a differentiated product to market before rivals can expand their ADC footprints.

From a market perspective, the endometrial cancer indication is strategically attractive. The disease’s rising incidence, coupled with limited post‑platinum options, creates a sizable addressable market. If sac‑TMT secures approvals in the U.S. and Europe, Merck could capture a significant share of a market projected to grow at double‑digit rates over the next five years. Moreover, the ongoing 17‑study TroFouse portfolio suggests Merck is building a platform that could be leveraged across multiple tumor types, amplifying the commercial upside.

However, the path forward is not without hurdles. Regulatory agencies will scrutinize the magnitude of OS benefit and the comparative safety profile, especially given the availability of other ADCs and emerging chemo‑immunotherapy combos. Additionally, global reimbursement environments, particularly in Europe, may demand robust health‑economic data to justify premium pricing. Merck’s ability to navigate these challenges will determine whether sac‑TMT becomes a cornerstone of its post‑Keytruda era or remains a niche offering.